Corundum Group Inc. Cuts Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Corundum Group Inc. lowered its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 6.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 402 shares of the medical equipment provider’s stock after selling 30 shares during the quarter. Corundum Group Inc.’s holdings in Intuitive Surgical were worth $210,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Godsey & Gibb Inc. raised its stake in Intuitive Surgical by 140.0% during the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 35 shares during the last quarter. MidAtlantic Capital Management Inc. purchased a new stake in Intuitive Surgical during the third quarter valued at $33,000. Decker Retirement Planning Inc. bought a new position in Intuitive Surgical in the fourth quarter valued at about $36,000. Capital Performance Advisors LLP purchased a new position in Intuitive Surgical in the third quarter worth about $38,000. Finally, DT Investment Partners LLC grew its stake in shares of Intuitive Surgical by 80.0% during the 3rd quarter. DT Investment Partners LLC now owns 81 shares of the medical equipment provider’s stock valued at $40,000 after purchasing an additional 36 shares during the period. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Price Performance

NASDAQ ISRG opened at $592.64 on Monday. The stock has a market capitalization of $211.09 billion, a PE ratio of 95.28, a P/E/G ratio of 4.66 and a beta of 1.39. Intuitive Surgical, Inc. has a 1-year low of $362.14 and a 1-year high of $597.68. The business has a 50 day simple moving average of $540.66 and a two-hundred day simple moving average of $499.19.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.24 by $0.32. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. The company had revenue of $2.04 billion for the quarter, compared to analysts’ expectations of $2.01 billion. On average, analysts anticipate that Intuitive Surgical, Inc. will post 5.45 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Gary S. Guthart sold 18,151 shares of the stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $511.63, for a total transaction of $9,286,596.13. Following the sale, the chief executive officer now owns 24,219 shares in the company, valued at approximately $12,391,166.97. This represents a 42.84 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Jamie Samath sold 270 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $540.15, for a total value of $145,840.50. Following the completion of the sale, the chief financial officer now owns 8,757 shares of the company’s stock, valued at approximately $4,730,093.55. This represents a 2.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 48,190 shares of company stock valued at $25,012,927 in the last three months. Corporate insiders own 0.80% of the company’s stock.

Analysts Set New Price Targets

ISRG has been the topic of several recent research reports. Truist Financial increased their price objective on shares of Intuitive Surgical from $570.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Stifel Nicolaus lifted their price target on shares of Intuitive Surgical from $525.00 to $610.00 and gave the stock a “buy” rating in a research note on Thursday, December 5th. Oppenheimer restated a “market perform” rating on shares of Intuitive Surgical in a research note on Friday, October 18th. JPMorgan Chase & Co. lifted their target price on Intuitive Surgical from $495.00 to $575.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Finally, Citigroup upped their price target on Intuitive Surgical from $567.00 to $640.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus price target of $554.17.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.